2023-09-07 13:38:45 ET
More on Medtronic, Insulet, etc.
- Compare metrics for MDT to PODD, TNDM
- Medtronic plc ( MDT ) Wells Fargo 2023 Healthcare Conference (Transcript)
- Medtronic: The Crossroads Of Its Growth Trajectory
- Tandem Diabetes: Cash Flow And Profitability Trends A Drag On Equity Performance, Reiterate Hold
- Medtronic Q1 2024 Earnings Review: Management Placates The Market
- Medtronic: The Tide Is Turning
- Insulet: Losing More Weight
- Medtronic plc ( MDT ) Q1 2024 Earnings Call Transcript
- Medtronic plc 2024 Q1 - Results - Earnings Call Presentation
- DexCom cites rising glucose monitor use amid weight loss therapy
- Insulet gains amid winning TRO in dispute with EOFlow, CEO insider buy
- Insulet spikes as CEO buys over $1M shares
- Medtronic gets EU approval for Inceptiv spinal cord stimulator
- Medtronic slips as FDA panel votes against blood pressure treatment
- Medtronic raises guidance as Q1 results exceed forecasts
- Medtronic Non-GAAP EPS of $1.20 beats by $0.09, revenue of $7.7B beats by $140M
- Can Medtronic beat negative forecasts with Q1 results?
For further details see:
Insulet, Tandem Diabetes drop as weight loss drugs impact insulin use